Literature DB >> 11100883

Immunological enhancement of primary tumor development and its prevention.

H Schreiber1, T H Wu, J Nachman, D A Rowley.   

Abstract

While it has been known for decades that the growth of tumor transplants can be enhanced immunologically, the potential significance of these previous findings to the development of primary tumors and the mechanisms of tumor enhancement has remained obscure. This review will summarize recent experiments indicating that primary tumor development can be enhanced by active immunization. The evidence suggests that antibodies, B cells and CD4+ T cells can play a critical role in enhancing the development of primary, tumors, whereas endogenous interferon-gamma (IFNgamma) can counteract enhancement. Thus, we envision two possible functions of IFNgamma: (i) preventing B cell and antibody enhancement and (ii) counteracting tumor promotion independent of T and B cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11100883     DOI: 10.1006/scbi.2000.0331

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  14 in total

1.  Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.

Authors:  Kristel Kodar; Jelena Izotova; Kersti Klaamas; Boris Sergeyev; Lilian Järvekülg; Oleg Kurtenkov
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

Review 2.  Harnessing B cells in immunotherapy.

Authors:  Marilia Cascalho; Jeffrey L Platt
Journal:  Immunotherapy       Date:  2016-02-09       Impact factor: 4.196

3.  B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.

Authors:  David J DiLillo; Koichi Yanaba; Thomas F Tedder
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

4.  Evaluation of humoral immunity in oral cancer patients from a nigerian referral centre.

Authors:  Victor I Akinmoladun; Olatubosun G Arinola; T Elumelu-Kupoluyi; Lucy O Eriba
Journal:  J Maxillofac Oral Surg       Date:  2012-09-25

Review 5.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.

Authors:  David G DeNardo; Pauline Andreu; Lisa M Coussens
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

Review 6.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15

7.  Liver metastases induce reversible hepatic B cell dysfunction mediated by Gr-1+CD11b+ myeloid cells.

Authors:  Mitchell Thorn; Gary R Point; Rachel A Burga; Cang T Nguyen; N Joseph Espat; Steven C Katz
Journal:  J Leukoc Biol       Date:  2014-08-01       Impact factor: 4.962

Review 8.  Polarized immune responses differentially regulate cancer development.

Authors:  Magnus Johansson; David G Denardo; Lisa M Coussens
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

9.  Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma.

Authors:  Hans-Udo Kasper; Uta Drebber; Dirk-Ludger Stippel; Hans-Peter Dienes; Anton Gillessen
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

Review 10.  Immunoglobulin expression in non-lymphoid lineage and neoplastic cells.

Authors:  Zhengshan Chen; Xiaoyan Qiu; Jiang Gu
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.